Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that high blood pressure is an independent risk factor for disease progression in both adult and paediatric patients with kidney disorders and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. Hypertension in CKD is not only associated with GFR loss, but increases cardiovascular risk, which is the leading source of mortality and morbidity in this population. Given this complex relationship between hypertension, CKD and CVD, beside an optimal management of BP in CKD is mandatory to break an established vicious pathophysiological cycle that leads to adverse outcomes. New promising molecules for the treatment of chronic kidney disease, with interesting mechanisms, particularly regarding their pathophysiological interactions with arterial hypertension, are available or under development and in the very next future they may change the way we treat high blood pressure in CKD patients.